Current heart valve repair (annuloplasty) rings and bands are designed for symmetric dilatation. The Carpentier-McCarthy-Adams IMR ETlogix Annuloplasty Ring is the first asymmetric ring designed to treat asymmetric dilatation.
- Corrects for the valvular insufficiency associated with Type IIIb mitral regurgitation.
- Decreased anteroposterior (AP) distance increases leaflet coaptation.
- Asymmetric 3-D reduced P2-P3 curvature design compensates for tethered P3 segment.
- Increased sewing margin in the P2-P3 region, marked with suture, designed to accommodate a double-suture row.
Edwards' IMR ETlogix Ring was created through collaboration with several key innovators in the field of heart valve repair, including Professor Alain Carpentier, chairman of the Department of Cardiovascular Surgery at the Hopital Europeen Georges Pompidou in Paris; Dr. Patrick McCarthy, director of cardiac transplantation at The Cleveland Clinic Foundation; and Dr. David Adams, professor and chairman of the Department of Cardiothoracic Surgery at Mount Sinai Medical Center, New York.
Dr. Adams is the co-inventor of the Edwards Lifesciences' Carpentier-McCarthy-Adams IMR ETlogix Annuloplasty Ring and Carpentier-Edwards Physio II ring. Icahn School of Medicine at Mount Sinai receives royalties from Edwards Lifesciences in connection with the sale of this product, but does not receive any royalties when the devices are implanted in patients at Mount Sinai.
Dr. Adams is the inventor of the Medtronic Tri-Ad™ Adams Tricuspid Annuloplasty Ring. Icahn School of Medicine at Mount Sinai receives royalties from Medtronic in connection with the sale of this product, but does not receive any royalties when the device is implanted in patients at Mount Sinai. Dr. Adams is also National Co-Principal Investigator of the FDA Medtronic-CoreValve Pivotal Trial and National Co-Principal Investigator of the FDA Medtronic APOLLO Pivotral Trial, designed to evaluate the Intrepid TMVR System.